Treatment with hormone analogues can challenge the precise measurement by interference with the routinely used immunoassays systems, related to the presence of autoantibodies in the serum, interference with associated therapy or the presence of altered forms of the hormone, with modified biological activity and/or immunoreactivity. In patients with acromegaly treated with the hGH antagonist Pegvisomant (PEG) (Somavert®), most of the assays are deeply

To evaluate whether serum GH and IGF1 levels achieved after 3 months treatment with somatostatin analogues (SSA) are concordant with the efficacy of SSA after longer treatment with the same dose. Patients and methods: From 71 patients with acromegaly treated with SSA in our clinic, in 38 of them (28 women, 10 men, aged 22–62 years) data on serum GH and IGF1 were available at baseline, after 3 months and at the last evaluation on the same SSA dose.

A long term follow – up of thyrotoxic patients treated surgically is required not only for early detection of hypothyroid patients with poor compliance with treatment, but also for revealing late postoperative hyperthyroidism. Regarding the prevalence of postoperative hyperthyroidism, two previous studies found that 16% relapsed after 20 years (Kalk WJ, 1978) and 19% of post – thyroidectomy thyrotoxicosis occurred 20 -50 years after surgical

Treatment with hormone analogues can challenge the precise measurement by interference with the routinely used immunoassays systems, related to the presence of autoantibodies in the serum, interference with associated therapy or the presence of altered forms of the hormone, with modified biological activity and/or immunoreactivity. In patients with acromegaly treated with the hGH antagonist Pegvisomant (PEG) (Somavert®), most of the assays are deeply

The aim of the study was to evaluate prevalence of hyerhomocysteinemia in hypothyroid patients and the effect of folic acid supplementation when serum homocysteine was over risk level . Subjects with moderate(Group1) and severe hypothyroidism(Group2) were evaluated before any therapy and after 6 months of combined folic acid with levothyroxine substitution. Homocysteine (Hcy), folic acid, thyroid hormones, lipids were measured for all subjects. Thyroglobulin,

In normal subjects growth hormone (GH) and insulin-like growth factor-I (IGF-I) have opposing effects on glucose metabolism. Active acromegaly is associated with insulin resistance (IR) and glucose intolerance although both GH and IGF-I are elevated. Our objective was to compare whether GH or IGF-I correlates more closely with IR and glucose intolerance in acromegaly. Basal serum IGF-I and GH, glucose and insulin during an oral glucose tolerance

Vascular changes are common in acromegaly (ACM). Current therapies can normalise the levels of both growth hormone (GH) and insulin-like growth factor (IGF1).To establish whether the ACM vascular changes in patients with effectively managed disease are different from those in patients with an active condition.64 ACM patients were tested for serum GH (random and during an oral glucose tolerance test) and IGF1. Ultrasonography of the right common carotid